NEW YORK (GenomeWeb) – Cypher Genomics has signed a co-promotion agreement with Illumina that lets the sequencing vendor offer Cypher's Coral biomarker discovery service to pharmaceutical companies.

Specifically, under the terms of the agreement, Illumina's sales force will market Coral as part of a solution to pharma that includes sequencing and its NextBio platform for data analytics and storage. Pharma firms could, for example, use the service to analyze small groups of patients in early clinical trials to discover genetic markers that are linked to therapeutic response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.